A new drug, tavapadon, has shown significant promise in treating Parkinson’s disease, offering patients a longer-lasting relief from symptoms such as stiffness, tremors, coordination issues, and movement problems. The once-daily pill is especially effective for patients already taking at least 400 mg of levodopa daily and experiencing “motor fluctuations,” a condition where medication wears off, causing symptoms to return. Levodopa has long been the standard treatment for Parkinson’s disease, but it is associated with side effects like sleep disorders, hallucinations, impulse control issues, and weight gain.
Tavapadon works by mimicking dopamine and targeting the D1/D5 receptors in the brain, unlike levodopa, which targets the D2/D3/D4 receptors. This novel mechanism of action allows tavapadon to provide similar benefits without the adverse effects associated with levodopa. In a pivotal global study, patients who took tavapadon experienced significantly more “on time” and less “off time” compared to those who received a placebo. Additionally, there were no significant differences in side effects between the tavapadon group and the placebo group, suggesting that the drug is well tolerated.
Although the study’s results are promising, they were based on a short-term trial, and researchers caution that long-term studies are necessary to confirm these findings. Dr. Hubert H. Fernandez, the lead author of the study, expressed optimism about tavapadon’s potential to help Parkinson’s patients, particularly those in the moderate to advanced stages of the disease. For newly diagnosed patients with less severe symptoms, tavapadon could potentially replace levodopa’s three-times-daily dosing regimen, offering the benefit of a once-daily pill. This could lead to a reduced risk of motor fluctuations and side effects, which often develop as levodopa is taken over time.
For patients with advanced Parkinson’s, tavapadon can be used in conjunction with levodopa to enhance its effectiveness and minimize side effects. Researchers believe that this new drug, by selectively stimulating dopamine receptors, could significantly improve the symptomatic treatment of Parkinson’s across all stages of the disease. As the number of Parkinson’s cases is expected to rise dramatically by 2050, drugs like tavapadon offer hope for improved quality of life for millions of patients.
AbbVie, the maker of tavapadon, plans to file for FDA approval soon, and the agency will review the drug’s application to determine if it will be approved for public use.
READ MORE: